High Cholesterol
Management Protect your heart before it asks.

Expert lipid management combining medication, evidence-based dietary guidance, and cardiovascular risk assessment to bring your cholesterol into a healthy range and meaningfully reduce your risk of heart attack and stroke.

Book an Appointment
Florida Insurances
Georgia Insurances
New York Insurances
South Carolina Insurances
North Carolina Insurances
More Than a Number Cholesterol That Actually Gets Managed

A cholesterol reading on a lab report means nothing without context. An LDL of 140 is a very different clinical situation in a 35-year-old with no risk factors than in a 55-year-old with diabetes, hypertension, and a family history of early heart disease. Dr. Akers interprets your lipid panel within your full cardiovascular risk profile and builds a management plan calibrated to what your numbers actually mean for you.

Whether your cholesterol is mildly elevated and manageable with dietary changes, or significantly elevated and requiring statin therapy, Dr. Akers develops a clear, evidence-based plan and tracks your response at every follow-up visit. The goal is not a lower number on paper. It is meaningfully reduced risk of a cardiac event over your lifetime.

Book a Cholesterol Consultation
High Cholesterol Management at Superior Health
High Cholesterol Management What We Manage

Cholesterol management goes beyond prescribing a statin. Dr. Akers evaluates your full lipid panel, calculates your cardiovascular risk, and builds a comprehensive plan addressing medication, diet, and all contributing factors. Explore what comprehensive lipid management covers below.

A lipid panel measures total cholesterol, LDL, HDL, triglycerides, and sometimes non-HDL cholesterol and LDL particle number. Dr. Akers interprets each value in context, understanding that LDL is not the only risk marker and that low HDL or elevated triglycerides carry independent cardiovascular risk.
Cholesterol management decisions are driven by cardiovascular risk, not cholesterol levels alone. Dr. Akers calculates your ten-year cardiovascular risk using validated scoring systems and uses this alongside your cholesterol values, family history, blood pressure, smoking status, and diabetes status to determine the intensity of treatment your situation warrants.
Statins are the most widely studied and effective class of cholesterol-lowering medications, reducing LDL by 30 to 50 percent depending on the agent and dose. Dr. Akers selects the appropriate statin and intensity based on your cardiovascular risk, LDL target, potential for drug interactions, and your tolerance of different statin agents.
For patients who cannot tolerate statins or require additional LDL lowering, non-statin options including ezetimibe, PCSK9 inhibitors, bempedoic acid, and fibrates are available. Dr. Akers identifies which agents are appropriate for your lipid pattern and coordinates prior authorization for PCSK9 inhibitors when indicated.
Dietary changes can reduce LDL by 15 to 25 percent in motivated patients. Dr. Akers provides specific, evidence-based guidance on saturated fat reduction, soluble fiber intake, plant sterols, omega-3 fatty acids, and dietary patterns including the Mediterranean diet that have demonstrated cardiovascular benefit in large clinical trials.
Elevated triglycerides above 150 mg/dL are an independent cardiovascular risk factor and a marker of metabolic dysfunction. Very high triglycerides above 500 mg/dL carry a risk of pancreatitis. Dr. Akers addresses elevated triglycerides through dietary guidance, weight management, and prescription omega-3 fatty acids or fibrates when needed.
Familial hypercholesterolemia is a genetic condition causing severely elevated LDL from birth, affecting approximately 1 in 250 people and significantly underdiagnosed. Patients with LDL above 190 mg/dL or early family cardiac history should be evaluated. Dr. Akers screens for FH and initiates intensive treatment when identified.
Muscle aches and weakness are the most common statin side effects and lead many patients to discontinue effective therapy unnecessarily. Dr. Akers manages statin intolerance through dose reduction, switching agents, alternate-day dosing, and CoQ10 supplementation, allowing most patients to continue therapy with a tolerable regimen.
Lipid levels should be checked four to twelve weeks after any new medication or dose change, then every three to twelve months once stable. Dr. Akers establishes your monitoring schedule and ensures liver function and CK are checked when clinically indicated during the first year of statin therapy.
Low HDL below 40 mg/dL in men and below 50 mg/dL in women is an independent cardiovascular risk factor. While medications that specifically raise HDL have had mixed results in clinical trials, lifestyle interventions including regular aerobic exercise, smoking cessation, and moderate alcohol reduction reliably improve HDL and overall cardiovascular risk.
Book a Cholesterol Consultation
Why It Matters Why Cholesterol Management Cannot Wait
Dr. Akers providing preventive care
01 Atherosclerosis Is Decades in the Making

Cholesterol-driven plaque builds in arterial walls silently over decades before producing symptoms. The heart attack at 55 began accumulating risk at 30. Early identification and management of elevated LDL reduces the total plaque burden that develops over a lifetime, meaningfully reducing the probability of a cardiac event even if your cardiovascular risk currently feels low.

02 LDL Target Matters More Than LDL Value

The right LDL goal depends on your overall cardiovascular risk. A patient with established coronary artery disease should have LDL below 70 mg/dL. A patient with multiple risk factors should target below 100 mg/dL. A low-risk patient may be well-managed at below 130 mg/dL. Dr. Akers sets your specific target based on your complete risk profile, not a blanket population cutoff.

03 Medication Alone Is Not the Full Answer

Statins are powerful tools but they work best when combined with dietary optimization, weight management, exercise, and smoking cessation. Dr. Akers addresses all modifiable cardiovascular risk factors simultaneously because the combination of interventions produces substantially better outcomes than medication alone.

Book an Appointment
Pap smear and cervical health screening
Understanding Your Lipids What Each Cholesterol Number Actually Means

LDL carries cholesterol into arterial walls where it can contribute to plaque formation. Higher LDL correlates directly with cardiovascular risk. HDL carries cholesterol away from arterial walls back to the liver for elimination. Higher HDL is protective. Triglycerides are a separate lipid fraction reflecting fat storage and metabolic health.

Total cholesterol alone is a poor predictor of cardiovascular risk because it combines LDL, HDL, and other fractions. A high total cholesterol driven by high HDL is very different from the same number driven by high LDL. Dr. Akers reviews each component individually and considers the full lipid profile in the context of your other risk factors.

Vaccines and immunizations at Superior Health Medical
Starting Statin Therapy What to Expect When Starting Medication

Statins typically reduce LDL by 30 to 50 percent within four to six weeks of starting therapy. Dr. Akers checks your lipid panel at four to twelve weeks after initiation to assess response and makes any necessary dose adjustments. Most patients tolerate statins without significant side effects.

The decision to start statin therapy is a collaborative one. Dr. Akers explains your ten-year cardiovascular risk, what LDL reduction you would achieve with medication versus lifestyle changes alone, and what the data shows about event reduction at your risk level. You make the decision with complete information rather than receiving a prescription without context.

Book Your Cholesterol Consultation
Frequently Asked Questions High Cholesterol
Questions Answered
LDL above 130 mg/dL is borderline high for average-risk individuals, above 160 mg/dL is high, and above 190 mg/dL is very high and warrants evaluation for familial hypercholesterolemia. The clinical significance of any LDL value depends on your overall cardiovascular risk profile.
Yes, significantly. Reducing saturated fat, eliminating trans fats, increasing soluble fiber, and following Mediterranean-style dietary patterns can reduce LDL by 15 to 25 percent. While this may not be sufficient for high-risk patients, dietary optimization enhances the effect of medication and improves overall cardiovascular outcomes.
Fasting for nine to twelve hours provides the most accurate triglyceride reading and therefore the most accurate calculated LDL. Non-fasting lipid panels are increasingly used for screening since LDL, HDL, and total cholesterol are only minimally affected by recent meals. Dr. Akers specifies whether fasting is required when ordering your labs.
Yes. Statins are among the most extensively studied medications in medicine, with decades of safety data. The most common side effect is muscle aches, affecting a minority of patients and typically resolving with dose adjustment. The cardiovascular benefit of statins in appropriate patients substantially outweighs their risks.
The decision to stop statin therapy should always be made with Dr. Akers based on your current cardiovascular risk. In some cases, significant lifestyle changes allow statin dose reduction or discontinuation under close monitoring. Most patients who need statin therapy benefit from long-term treatment. Stopping without guidance typically results in LDL returning to previous levels within weeks.
Familial hypercholesterolemia is a genetic disorder causing severely elevated LDL from birth due to impaired LDL receptor function. LDL levels in FH are typically above 190 mg/dL and can exceed 300 mg/dL. Without treatment, patients have dramatically elevated lifetime cardiovascular risk. It affects approximately 1 in 250 people and is significantly underdiagnosed.
LDL carries cholesterol from the liver to peripheral tissues and contributes to atherosclerotic plaque when oxidized. Higher LDL is associated with higher cardiovascular risk. HDL performs reverse cholesterol transport, carrying cholesterol back to the liver for elimination. Higher HDL is protective and associated with lower cardiovascular risk.
Triglycerides are a separate fat fraction reflecting caloric excess, refined carbohydrate and alcohol intake, and metabolic dysfunction. Elevated triglycerides carry independent cardiovascular risk. They respond more to dietary intervention, particularly alcohol and refined carbohydrate reduction, than to statin therapy.
PCSK9 inhibitors including evolocumab and alirocumab are injectable biologics that reduce LDL by 50 to 60 percent on top of statin therapy. They are indicated for patients with very high cardiovascular risk, statin intolerance, or familial hypercholesterolemia who cannot achieve adequate LDL reduction with oral agents alone.
Regular aerobic exercise primarily raises HDL and lowers triglycerides. Its direct effect on LDL is modest, typically 5 to 10 percent. However, exercise improves overall cardiovascular health through multiple mechanisms beyond lipid modification and is a standard component of every cardiovascular risk reduction plan.
Adults without risk factors should have a baseline lipid panel by age 35 for men and age 45 for women, or earlier with risk factors. After starting treatment, labs are checked at four to twelve weeks to assess response, then annually once stable.
Genetics plays a significant role in cholesterol levels. Familial hypercholesterolemia is the most extreme example, but polygenic contributions to LDL elevation are common. A strong family history of high cholesterol or early heart disease warrants earlier and more aggressive lipid screening and management.